What Is AgomAb Therapeutics NV (AGMB) Worth in 2026?
According to the CirclFi Deep Alpha Valuation Engine, the balance of valuation evidence tilts cautious on AgomAb Therapeutics NV at its current price of $12.63. The composite intrinsic value is estimated at $10.54 (-16.5% average return), with 4 models flagging overvaluation risk. The most optimistic model, First Chicago, places fair value at $23.58 (+86.7%), while ML-RIV — the most conservative — estimates $1.38 (-89.1%). This +175.7% gap reflects genuine analytical uncertainty about AgomAb Therapeutics NV's intrinsic worth.
What Do the Models Say About AGMB?
7 of 13 models are currently active for AGMB. Of these, 2 models suggest upside while 5 models suggest overvaluation. The Bayesian DCF estimates AGMB's intrinsic value at $3.35, implying -73.5% downside from the current price. See which stocks rank higher →
How Does AGMB Rank in Biotechnology?
Among 76 Biotechnology stocks, AGMB ranks #74 by Quality of Company score. CirclFi's QOC score of 2.1/10 evaluates 32 fundamental signals. A score of 2.1 signals below-average fundamentals.
See all Most Undervalued Biotechnology Stocks →
As a biotech sector, AgomAb Therapeutics NV operates in a sector where partnership revenue is a critical driver of valuation. Investors evaluating AGMB should weigh these sector-specific dynamics alongside our model-derived fair values.
Is AGMB a Value Trap?
The Value Trap algorithm is not active for AGMB. The score cross-references apparent undervaluation against fundamental deterioration signals. Browse lowest value-trap stocks →
Multi-Model Methodology
7 of 13 models are active for AgomAb Therapeutics NV. Moderate coverage provides meaningful perspective. Each model applies a fundamentally different valuation philosophy. See the complete methodology →
According to the CirclFi 32-factor quality framework, AgomAb Therapeutics NV's fundamental quality profile registers 2.1/10. This concerning score captures the company's profitability depth, growth consistency, balance sheet resilience, and shareholder return track record.
The gap between the most bullish and bearish model spans +175.7% — demonstrating why single-model analysis is dangerous. Browse all stocks with 13-model coverage →
Data Sources & Confidence
Every AGMB valuation is built from SEC EDGAR XBRL filings — 700+ standardized financial tags. Macroeconomic context from FRED calibrates discount rates, while GDELT news sentiment feeds into our Sentiment SOTP model. All pipelines run daily. Read the complete data methodology →
Across AGMB's 7 active models, average confidence is 2%. Lower confidence may reflect limited history or high volatility.
CirclFi's output is a research starting point, not a buy/sell signal. All data updates daily. Read the full methodology →
Buy with Gumroad